Allergan (AGN) Earning Somewhat Favorable Press Coverage, Report Shows

News coverage about Allergan (NYSE:AGN) has been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Allergan earned a media sentiment score of 0.00 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.8196588630364 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

Shares of Allergan (NYSE:AGN) opened at $172.51 on Friday. The stock has a market capitalization of $59,380.00, a price-to-earnings ratio of -7.64, a PEG ratio of 1.32 and a beta of 1.19. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. Allergan has a 52-week low of $160.07 and a 52-week high of $256.80.

Allergan (NYSE:AGN) last announced its earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.06 by $0.09. The company had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. Allergan’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.32 earnings per share. research analysts anticipate that Allergan will post 16.27 EPS for the current fiscal year.

A number of research analysts have issued reports on AGN shares. Zacks Investment Research lowered Allergan from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Deutsche Bank set a $251.00 price target on Allergan and gave the stock a “buy” rating in a research report on Tuesday, October 17th. TheStreet lowered Allergan from a “c-” rating to a “d+” rating in a research report on Monday, December 4th. Piper Jaffray Companies set a $227.00 price objective on Allergan and gave the company a “hold” rating in a report on Friday, October 6th. Finally, JPMorgan Chase & Co. restated a “buy” rating and issued a $275.00 price objective on shares of Allergan in a report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $227.56.

In related news, Director Christopher J. Coughlin bought 10,000 shares of the business’s stock in a transaction dated Tuesday, December 5th. The shares were bought at an average cost of $163.30 per share, with a total value of $1,633,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Meury sold 11,807 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The disclosure for this sale can be found here. Insiders have bought 17,630 shares of company stock worth $2,890,057 over the last ninety days. 0.36% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Insider Buying and Selling by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with's FREE daily email newsletter.

Leave a Reply